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Abstract The Calcyclin binding protein and Siah-1
interacting protein (CacyBP/SIP) protein is highly expres-
sed in mammalian brain as well as in neuroblastoma NB2a
cells and pheochromocytoma PC12 cells. This protein
interacts with several targets such as cytoskeletal proteins
or ERK1/2 kinase and seems to be involved in many cel-
lular processes. In this work we examined a post-transla-
tional modification of CacyBP/SIP which might have an
effect on its function. Since theoretical analysis of the
amino acid sequence of CacyBP/SIP indicated several
lysine residues which could potentially be sumoylated we
checked experimentally whether this protein might be
modified by SUMO attachment. We have shown that
indeed CacyBP/SIP bound the E2 SUMO ligase, Ubc9, in
neuroblastoma NB2a cell extract and was sumoylated in
these cells. By fractionation of NB2a cell extract we have
found that, contrary to the majority of SUMO-modified
proteins, sumoylated CacyBP/SIP is present in the cyto-
plasmic and not in the nuclear fraction. We have also
established that lysine 16 is the residue which undergoes
sumoylation in the CacyBP/SIP protein.
Keywords CacyBP/SIP  Neuroblastoma NB2a
cells  Post-translational modification  SUMO1
Abbreviations
CacyBP/SIP Calcyclin binding protein and Siah-1
interacting protein
PAGE Polyacrylamide gel electrophoresis
SDS Sodium dodecyl sulfate
SUMO Small ubiquitin related modifier
Ubc9 SUMO conjugating enzyme
Introduction
The CacyBP/SIP protein (S100A6 binding protein and
Siah-1 interacting protein) was originally discovered in
Ehrlich ascites tumor cells as an S100A6 binding protein
(reviewed in [1]). Later, CacyBP/SIP was found in different
mouse, rat and human tissues. A particularly high level of
CacyBP/SIP was shown in brain [2, 3] as well as in neu-
roblastoma NB2a and pheochromocytoma PC12 cells. The
immunofluorescence studies have indicated that CacyBP/
SIP is present mainly in the cytoplasm and, under certain
conditions, also in the nucleus [4, 5]. CacyBP/SIP has
several interacting partners. Among them are members of
the S100 protein family, for example S100A6 [6], cyto-
skeletal proteins such as tubulin, actin, tropomyosin as well
as ERK1/2 kinase [7–10]. The interaction between CacyBP/
SIP and ERK1/2 inhibited phosphorylation of the Elk-1
transcription factor in the nuclear fraction of neuroblastoma
NB2a cells and, interestingly, this effect was due to the
phosphatase activity of CacyBP/SIP toward ERK1/2 [11].
Sumoylation is a post-translational modification in
which the SUMO (Small Ubiquitin Related Modifier)
molecule is attached to the target protein. Sumoylation
belongs to the same group of modifications as ubiquitina-
tion or neddylation. There are four SUMO proteins,
SUMO1, SUMO2, SUMO3 and SUMO4. Attachment of
SUMO usually occurs on a lysine residue of the target
protein located in the consensus sequence wKxD/E, where
‘‘w’’ represents a hydrophobic residue and ‘‘x’’—any sort
of amino acid residue. However, sumoylation might also
U. Wasik  A. Filipek (&)




Neurochem Res (2013) 38:2427–2432
DOI 10.1007/s11064-013-1155-4
occur at lysine residues outside the consensus motif. This
reaction is catalyzed by three groups of enzymes: E1-
activating enzyme, E2-conjugating enzyme and E3-ligase.
Up to now, several E3 ligases have been identified and only
one E2-conjugating enzyme, namely Ubc9. Sumoylation
was shown to be important for many cellular processes
such as cell cycle regulation, transcription, protein degra-
dation or chromatin organization [12–14].
Since the theoretical analysis indicated that several
lysine residues in the amino acid sequence of CacyBP/SIP
might be modified by the SUMO moiety, in this work,
using different techniques, we checked the hypothesis that
this protein might be sumoylated in neuroblastoma NB2a




Mouse neuroblastoma NB2a cells were grown in MEM
containing 2 mM L-glutamine, 1 mM sodium pyruvate,
25 mM sodium bicarbonate, 10 % fetal bovine serum,
0.1 mM non-essential amino acids, 100 U/ml penicillin,
100 lg/ml streptomycin and 0.25 lg/ml fungizone. The
medium was changed every 2–3 days and cells were pas-
saged when confluent.
Plasmids
Plasmid pGW1-Ubc9-HA was prepared as follows. The
coding region of the Ubc9 protein (E2 SUMO ligase) was
obtained by PCR reaction, using cDNA from neuroblas-
toma NB2a cells as a template and the appropriate primers:
forward 5 0-TATAGATCTAATGTCGGGGAT-30 and
reverse 50-TATGAATTCTTATGAGGGCGC-30. The PCR
product was purified from the agarose gel and digested
with EcoRI and BglII. Then it was introduced into the
pGW1-HA plasmid (gift from Prof. J. Jaworski, Interna-
tional Institute of Molecular and Cell Biology, Warsaw)
previously digested with the same enzymes. After trans-
formation into Escherichia coli (TOP10F0) and purifica-
tion, the correctness of the sequence of the cloned insert
was confirmed by DNA sequencing.
Plasmids encoding FLAG-tagged CacyBP/SIP with
various lysine residues mutated to arginine were generated
employing site-directed mutagenesis using pCMV3x
FLAG-CacyBP/SIP as a template [7]. The reaction was
performed using Pfu polymerase and primers listed in
Table 1. To remove the parental DNA template the PCR
product was treated with DpnI endonuclease. The intro-
duced mutations were verified by DNA sequencing.
Plasmids pCMV-FLAG-Ubc9 encoding FLAG-tagged
Ubc9 and pEYFP-SUMO1 encoding SUMO moiety fused
with EYFP were a generous gift from Prof. J. M. Henley
(Department of Biochemistry, School of Medical Sciences,
University of Bristol, UK).
Cell Transfection and Co-precipitation of CacyBP/SIP
with Ubc9
To check if Ubc9 co-precipitates with CacyBP/SIP in the
cell extract, neuroblastoma NB2a cells were co-transfected
with plasmids encoding Ubc9-HA (pGW1-HA-Ubc9) and
CacyBP/SIP-FLAG (pCMV3xFLAG-CacyBP/SIP) or, as a
Table 1 Sequences of primers















K147R Fw: GTTCAAAAAAAGTCCGGACT GATACAGTA
Rv: ACTGTATCAGTCCGGACTTTTTTTGAACT
K208R Fw: CGGAGACGATGATATGAGG CGAACCATTAA
Rv: TATTAATGGTTCGCCTCATATCATCGTCTC
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control, encoding Ubc9-HA only (pGW1-HA-Ubc9 and
pCMV3xFLAG) using Lipofectamine 2000 (Invitrogen).
After 24 h cells were harvested and suspended in IP buffer
containing 50 mM Tris–HCl (pH 7.5), 50 mM KCl, 1 mM
EDTA, 1 mM MgCl2, 0.1 % Triton X-100, protease
inhibitor mixture (Complete, Roche Molecular Biochemi-
cals) and 20 mM N-ethylmaleimide (NEM). Next, the
extract was centrifuged for 10 min at 16,0009g. Proteins
from the supernatant fraction (800 lg) were incubated with
40 ll of anti-FLAG M2 agarose resin (Sigma), previously
equilibrated with IP buffer, for 3 h at 4 C. Unbound
proteins were removed, the resin was washed five times
with IP buffer and bound proteins were eluted from the
anti-FLAG agarose resin using 0.1 M glycine–HCl, pH 3.5.
Proteins were then separated on 10 % SDS gel and iden-
tified by Western blot using the appropriate antibodies.
Sumoylation of CacyBP/SIP in Neuroblastoma NB2a
Cells
To check the sumoylation of CacyBP/SIP, neuroblastoma
NB2a cells were co-transfected with plasmids: pEYFP-
SUMO1, pCMV-FLAG-Ubc9 and pCMV3xFLAG-Cacy-
BP/SIP. The cells were subjected to fractionation in order
to obtain cytoplasmic and nuclear fractions using NE-PER
extraction reagents (Pierce) according to the manufac-
turer’s instruction (purity of the cytoplasmic and nuclear
fraction was checked using anti-GAPDH or anti-HDAC1
antibodies, respectively) or suspended directly in the RIPA
buffer containing: 10 mM Tris–HCl (pH 7.5), 150 mM
NaCl, 1 mM EDTA, 1 mM EGTA, 0.5 % NP-40, 1 %
Triton X-100. Proteins from the cell extract (80 lg) were
analyzed by Western blot using monoclonal antibodies
against CacyBP/SIP (Abcam).
SDS-PAGE and Western Blotting
Gel electrophoresis with 10 % (w/v) polyacrylamide con-
taining 0.1 % SDS was performed by the method of Lae-
mmli [15]. Proteins were transferred electrophoretically
onto nitrocellulose and identified using primary antibodies:
mouse anti-CacyBP/SIP monoclonal antibody (1:1,000;
Abcam), or mouse anti-Ubc9 antibody (1:1,000; Sigma).
After washing with TBS-T buffer (50 mM Tris, pH 7.5,
200 mM NaCl, 0.05 % Tween 20) the blots were incubated
with secondary goat anti-mouse IgG antibodies conjugated
to horseradish peroxidase (1:10,000) (Jackson Immunore-
search Laboratories). After three washes with TBS-T and
two washes with TBS (50 mM Tris, pH 7.5, 200 mM
NaCl) blots were developed with the ECL chemilumines-
cence kit (Amersham Biosciences) followed by exposure
against an X-ray film.
Results
CacyBP/SIP Co-precipitates with Ubc9
in Neuroblastoma NB2a Cells
The CacyBP/SIP amino acid sequence was analyzed by the
SUMOsp 2.0 online tool (http://sumosp.biocuckoo.org). As
it is shown in Fig. 1, several potential sumoylation sites
were identified. Among them were lysine residues in
positions 16, 37, 43, 49, 52, 53, 147 and 208.
In order to establish whether CacyBP/SIP might be su-
moylated we first checked if it bound the SUMO conjugating
enzyme, Ubc9. To examine this, a co-immunoprecipitation
assay was performed. Ubc9-HA and CacyBP/SIP-3xFLAG
were transiently overexpressed in mouse neuroblastoma
NB2a cells and proteins from the cell extract were incubated
with anti-FLAG M2 affinity resin to isolate CacyBP/SIP-
3xFLAG with its targets. Proteins in the elution fraction
were examined by Western blot analysis for the presence of
Ubc9. As shown in Fig. 2, Ubc9-HA co-precipitated with
CacyBP/SIP-3xFLAG, indicating that CacyBP/SIP and
Ubc9 interacted with one another and suggesting that
CacyBP/SIP might undergo sumoylation.
CacyBP/SIP is Sumoylated in Neuroblastoma NB2a
Cells and is Present in the Cytoplasmic Fraction
To examine if CacyBP/SIP is sumoylated in the cell,
neuroblastoma NB2a cells were transfected with plasmids
encoding proteins that enhance this modification i.e., Ubc9
and SUMO as described in Materials and Methods. As it is
seen in Fig. 3A an additional band recognized by anti-
CacyBP/SIP antibody at the level of 75 kDa becomes
visible. This band, representing EYFP-SUMO1-CacyBP/
SIP-3xFLAG, is detected in cells overexpressing SUMO1-
EYFP, Ubc9-FLAG and CacyBP/SIP-3xFLAG but not in
cells overexpressing only CacyBP/SIP-3xFLAG. In order
to establish the subcellular localization of sumoylated
Fig. 1 The amino acid sequence of mouse CacyBP/SIP (accession
number NP_033916). Lysine residues, identified by SUMOsp 2.0
tool, which might be potentially sumoylated are marked in bold (these
with high probability) or underlined (these with lower probability)
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CacyBP/SIP, NB2a cells were subjected to fractionation
into nuclear and cytoplasmic fractions. As it can be seen in
Fig. 3B, the EYFP-SUMO1-CacyBP/SIP-3xFLAG band
migrating at the level of 75 kDa is present in the cyto-
plasmic fraction and not in the nuclear one. In the nuclear
fraction a band migrating at the level of 66 kDa was
detected with anti-CacyBP/SIP antibody, which most
probably represents CacyBP/SIP dimer [16].
Lysine 16 is an Acceptor of SUMO in CacyBP/SIP
The theoretical analysis performed by the SUMOsp 2.0
online tool allowed us to identify several lysine residues in
the CacyBP/SIP amino acid sequence that might undergo
sumoylation. To establish which lysine residue is modified
by SUMO1, several mutants, in which particular lysine
residues were replaced by arginine, were constructed.
Interestingly, only the mutant in which lysine in position
16 was changed to arginine was not sumoylated. This
observation allowed us to conclude that this particular
lysine is a target for SUMO1 attachment (Fig. 3C).
Discussion
The CacyBP/SIP protein is distributed in various tissues
and cells, mainly in brain neurons or in established cell
lines of neuronal origin such as neuroblastoma NB2a cells,
and seems to play a role in various cellular processes
(reviewed in [1]. Recently, we have shown that CacyBP/
SIP has phosphatase activity and that this activity depends
on CacyBP/SIP phosphorylation [11, 17, 18]. To explore
the post-translational modifications of CacyBP/SIP, that
might have an impact on its function, in this work we
focused on sumoylation. Theoretical analysis indicated
several lysine residues in the CacyBP/SIP sequence which
might be modified by the SUMO molecule. Indeed, our
experimental data confirmed that CacyBP/SIP was
Fig. 2 Co-immunoprecipitation of CacyBP/SIP with Ubc9 in NB2a
cell extract. Cells were co-transfected with pGW1-HA-Ubc9 and
pCMV3xFLAG-CacyBP/SIP (designated as HA-Ubc9 and 3xFLAG-
CacyBP/SIP) or pGW1-HA-Ubc9 and pCMV3xFLAG (designated as
HA-Ubc9). Proteins from the extract were used directly for Western
blot analysis (80 lg) or incubated with anti-FLAG M2 affinity resin
(800 lg). Proteins co-precipitated with CacyBP/SIP-3xFLAG were
examined by Western blot using anti-Ubc9 or anti-CacyBP/SIP
antibodies. Western blot images representative for 3 experiments
performed are shown
Fig. 3 Sumoylation of
CacyBP/SIP in neuroblastoma
NB2a cells. Western blot
developed with anti-CacyBP/
SIP antibody shows sumoylated
CacyBP/SIP in cell extract
(A) and in subcellular fractions
of NB2a cells (B). In each case
80 lg of protein was applied on
the gel. Panel C shows that wild
type CacyBP/SIP (WT) is
sumoylated in NB2a cell extract
while K16R CacyBP/SIP
mutant is not. Western blot
images representative for 3
experiments performed are
shown
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sumoylated in neuroblastoma NB2a cells, and moreover,
we identified a lysine residue involved in this modification.
Sumoylation was shown to strongly determine the sub-
cellular localization of proteins and to be important in key
cellular processes. For a long time this modification was
considered to be limited to the nucleus, however, the evi-
dence of cytoplasmic protein sumoylation, especially in the
nervous system, has emerged recently [19]. For instance,
sumoylation of the cytoplasmic La protein is important for
the axonal transport. Sumoylated La protein interacts with
dynein, which facilitates the retrograde transport in neu-
rons, whereas its non-sumoylated form interacts with
kinesin, which is responsible for the anterograde transport
[20]. Sumoylation of cytoskeletal proteins seems to be
implicated in different cytoskeletal functions such as den-
dritic spine formation [21]. Since CacyBP/SIP interacts
with tubulin, actin and tropomyosin [7–9], one can spec-
ulate that CacyBP/SIP sumoylation may play a role in the
organization of the cytoskeleton, especially during cell
differentiation.
Recently, it has been reported that sumoylation might
have an effect on the enzymatic activity of some proteins.
For instance, it was shown, that SUMO attachment regu-
lates the activity of a protein tyrosine phosphatase, PTP1B.
Sumoylation of PTP1B inhibits its activity [22] and affects
its subcellular localization [23]. Another example is the
focal adhesion kinase, FAK. Sumoylation of FAK dra-
matically increases its autophosphorylation and activity
[24]. Regarding CacyBP/SIP, it is known that it exhibits
phosphatase activity towards ERK1/2 and tau [11, 18] but
we have not seen any effect of CacyBP/SIP sumoylation on
dephosphorylation of these substrates (data not shown).
To explain the lack of effect of CacyBP/SIP sumoyla-
tion on its functions we have analyzed the structure of the
modified protein. For that we have employed a molecular
modeling method using the available structures of CacyBP/
SIP N-terminus and of SUMO1. As it can be seen in Fig. 4,
the N-terminal part of CacyBP/SIP forms two anti-parallel
helices (47 amino acids). The K16 residue is located on the
side of the helix not facing the other helix therefore the
attachment of a moiety, even one as large as SUMO1,
should not significantly affect the structure of CacyBP/SIP.
The exposed location of the SUMO moiety on CacyBP/SIP
makes it easily accessible for other proteins. Interestingly,
sumoylation, similarly to some other posttranslational
modifications, for instance acetylation, is regarded as a
modification that may help to assemble large protein
complexes since the SUMO moiety can be recognized by a
SUMO interacting motif (SIM) present in other proteins
[25]. Thus, CacyBP/SIP sumoylation may facilitate its
interaction with other protein partners. This feature is
important since CacyBP/SIP was postulated to be a com-
ponent of multiprotein complexes [26].
Taken together, the CacyBP/SIP protein is involved in
many cellular processes under normal and pathological
conditions but little is known about the mechanisms which
determine its activity. CacyBP/SIP sumoylation might be
considered as an important modification that might facili-
tate the formation of multiprotein complexes involved in
the organization of the cytoskeleton, especially during
differentiation of neuronal type of cells.
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